Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jilin Tancheng Pharmaceutical is a specialized pharmaceutical manufacturer based in Meihekou, Jilin Province, China, and operates as a significant subsidiary of Gloria Pharmaceuticals. The company focuses on the development and production of injectable drugs, particularly those derived from animal tissues and herbal extracts. Its most prominent product is the Deer Bone Collagen Extract Injection (Luguaduotai), which holds a substantial market share in China for treating orthopedic conditions such as osteoarthritis and fractures. In addition to orthopedics, the company maintains a diverse portfolio including cardiovascular treatments and anti-infective agents like cefotaxime. Jilin Tancheng operates advanced manufacturing facilities that adhere to national GMP standards, supporting its role as a key production hub for its parent company. The firm primarily serves the domestic Chinese healthcare market through an established hospital-based distribution network.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jilin Tancheng Pharmaceutical.